Latest news

Syngeneic tumor models were becoming invaluable for preclinical development and evaluation of immuno-based therapies. Nevertheless, the immunometabolic features of these tumors models, which may likely underlie responsiveness to immunotherapies, are still not well understood and become thus primordial to be defined for tumor model characterization and selection of the appropriate ones, for target validation, drug development, and assessment of the efficacy potential of drug candidates.

Explicyte is planning a new in vivo shuttle session by early March, thereby providing an opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic subcutaneously-implanted tumor models, over studies where a significant cost part will be supported by ourselves.

Besides their antimicrobial functions, neutrophils are likely infiltrating many types of tumors and increasing evidence correlate the tumor-associated neutrophils (TANs) with poor clinical outcome thereby supporting their role in tumor development. Recruitment of such TANs is indeed driven by key chemokines including the prototypical CXCL8 (IL8) or CXCL1 produced by tumor cells or its microenvironment. In turns, TANs might be involved in the recruitment of other immune cell populations (eg. Tregs, TAMs, etc), all together maintaining the local immunosuppressive microenvironment. Therefore acting on neutrophil recruitment and migration represents a valuable cancer immunotherapy strategy.

To get the opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic model, do not miss our new in vivo glioblastoma shuttle session by mid-January 2019, in which a cost part will be supported by Explicyte.

The immunological synapse that occurs between T lymphocytes and Dendritic cells (DCs) is a key component of an effective immune response and is controlled by a combination of stimulatory and inhibitory signals – also called immune checkpoints. As to trigger a better anti-tumor immune response, interventions through a fine-tuning of these control signals within the immunological synapse represent one of the most promising cancer immunotherapy strategies.

Activation of T cell immune response through regulation of immune checkpoint pathways is one of the most considerable strategies being employed in cancer immunotherapy, either as individual or in combination. While development of checkpoint inhibitors blocking PD1/PDL1 interaction is still a major interest thereby contributing to the suppression of tumor immune resistance, accurate identification and robust pharmacological characterization of modulatory agents thus become key and should be guaranteed through the assays.

To get the opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic model, do not miss our new in vivo glioblastoma shuttle session by mid-June, 2018. In this session, only experimental test groups-related costs will be covered by Sponsors ; control groups being supported by Explicyte.

Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded, through a highly-competitive selection process, the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.

In view of the success of our previous shuttle sessions, which offered the opportunity to run efficacy studies in a cost-saving manner, we are planning a new shuttle on the orthotopic (OT) 4T1 mammary fat pad mouse model, which will be held in late March.

Modulation of the immune system function aiming at enhancing the responsiveness potential of immune cells is one of the current promising challenges in cancer immunotherapy. Upon activation, immune (T) cells undergo clonal expansion followed by differentiation into effectors to mediate cytotoxicity and/or cytokine release. Modulating the mechanisms underlying immune cell activation is key for the development of innovative approaches to promote immune function and tackle tumor progression.